Articles related to ALZHEIMER'S/DEMENTIA

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

The TRAILBLAZER-ALZ Randomized Clinical Trial According to the findings of post-hoc analysis for patients who received donanemab treatment, baseline amyloid levels were directly related to the extent of amyloid reduction and inversely related to the likelihood of obtaining total amyloid clearance. In patients with complete amyloid clearance and in brain areas discovered later in the pathologic sequence, the donanemab-induced slowing of tau was more severe. To support the aforementioned findings, data from additional trials would be crucial, particularly information on treatment response according to APOE ε4 status.

The disappointing findings from the $100 million National Institutes of Health (NIH) project, the first-ever prevention trial for Alzheimer’s disease, which tested an antiamyloid monoclonal antibody called crenezumab in people with the Paisa mutation, the most common cause of familial, early-onset Alzheimer’s disease.

This study enrolled individuals with AD who had been on a stable dose of donezepil forat least 90 days. They were then treated for 12 weeks with the addition of themodulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101had mean improvement of approximately 2 points on the Alzheimer DiseaseAssessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plusplacebo showed declines on ADAS-Cog.

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.